Document Detail


Acute consequences of ischemic myocardial damage.
MedLine Citation:
PMID:  2483224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The current revolution in the treatment of acute myocardial infarction by means of thrombolytic therapy has as its underlying strategy three aims: early restoration of the blood flow in order to salvage jeopardized but still viable tissues; limitation of acute consequences of ischemic heart disease, such as infarct size, ventricular fibrillation, and pericardial effusion; and preservation, as far as possible, of ventricular function. It is also hoped that these three achievements will result in reduced short- as well as long-term mortality rates. The techniques employed in this overall strategy are still under investigation, and several leading pharmacological compounds vie for supremacy: streptokinase (SK) and its anisoylated form (APSAC), recombinant technique tissue type plasminogen activator (rt-PA), and urokinase (UK) with or without prourokinase (PUK). Other pharmacological agents, such as angiotensin converting enzyme (ACE) inhibitors, beta-blockers, Ca2+ antagonists, and O2 radical scavengers, might find here their "finest hour" yet. In addition, the underlying anatomy may require early or, where needed, delayed PTCA, backed up by coronary artery bypass grafting. Thus, the tactics of the intervention may vary from case to case and indeed from center to center depending on experience and facilities, but the strategic conclusion is clearly the same: early reperfusion is a must if one wishes to save ischemic but still viable tissue.
Authors:
P G Hugenholtz; P W Serruys; M L Simoons; F Vermeer
Related Documents :
7963104 - Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase ...
2807704 - Therapy for myocardial infarction: effect on trends in coronary disease mortality.
1906904 - Depression of factor xii-dependent fibrinolytic activity characterizes patients with ea...
17963464 - Fibrinolytic agents for the management of st-segment elevation myocardial infarction.
16008154 - Directional coronary atherectomy in 2005.
23901674 - Transradial primary percutaneous coronary intervention - experience from a tertiary car...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  14 Suppl 9     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1989  
Date Detail:
Created Date:  1990-04-09     Completed Date:  1990-04-09     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S1-11     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Erasmus University, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Cardiomyopathies / etiology,  physiopathology*
Coronary Disease / complications,  physiopathology*
Humans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanism of action of serotonin on frog adrenal cortex.
Next Document:  Treatment of hypertension and ischemic heart disease.